TG Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 01, 2023 at 07:30 am EDT
Share
TG Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 165.82 million compared to USD 0.094 million a year ago. Net income was USD 113.93 million compared to net loss of USD 35.82 million a year ago. Basic earnings per share from continuing operations was USD 0.8 compared to basic loss per share from continuing operations of USD 0.26 a year ago. Diluted earnings per share from continuing operations was USD 0.73 compared to diluted loss per share from continuing operations of USD 0.26 a year ago.
For the nine months, revenue was USD 189.69 million compared to USD 2.71 million a year ago. Net income was USD 27.09 million compared to net loss of USD 145.34 million a year ago. Basic earnings per share from continuing operations was USD 0.19 compared to basic loss per share from continuing operations of USD 1.08 a year ago. Diluted earnings per share from continuing operations was USD 0.19 compared to diluted loss per share from continuing operations of USD 1.08 a year ago.
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
TG THERAPEUTICS, INC. 
